Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

NCT04777981
View directory record Official record
Conditions
COVID-19, SAR
Interventions
CBDRA60 supplement, Placebo
Dietary Supplement
Lead sponsor
Anewsha Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hanover, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 2 Interventional

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

NCT05077332
View directory record Official record
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV-2 Infection, SARS-CoV-2 Acute Respiratory Disease, COVID-19
Interventions
Famotidine, Celecoxib, Placebo
Drug · Other
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

NCT04342663
View directory record Official record
Conditions
COVID 19, Coronavirus
Interventions
Fluvoxamine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Belleville, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 9, 2021 · Synced Oct 26, 2026, 5:19 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cellular Senescence and COVID-19 Long-Hauler Syndrome

NCT04903132
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 5:19 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19

NCT04336332
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Hydroxychloroquine Sulfate + Azithromycin, Hydroxychloroquine Sulfate
Combination Product · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Livingston, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 26, 2026, 5:19 AM EDT
Completed No phase listed Observational

Natural History Study of COVID-19 Using Digital Wearables

NCT04927442
View directory record Official record
Conditions
COVID-19 Virus Disease
Interventions
Not listed
Lead sponsor
National Institute on Minority Health and Health Disparities (NIMHD)
NIH
Eligibility
18 Years to 65 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961
View directory record Official record
Conditions
Critical Confirmed Coronavirus Disease (COVID)-19
Interventions
Sirukumab, Placebo, Standard of Care (SOC)
Drug · Other
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years to 84 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
16
States / cities
Long Beach, California • Newport Beach, California • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy

NCT03554265
View directory record Official record
Conditions
Traumatic Brain Injury, Fatigue, Cognitive Impairment, COVID-19
Interventions
Somatropin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 26, 2026, 5:19 AM EDT
Recruiting Phase 1 Interventional

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

NCT07464314
View directory record Official record
Conditions
Influenza, Human+COVID-19
Interventions
Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine, Licensed Seasonal Influenza Vaccine, Licensed COVID-19 Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Little Rock, Arkansas • Fair Oaks, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 5:19 AM EDT
Completed No phase listed Observational

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

NCT04588363
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
Interventions
SARS-CoV-2 and/or MIS-C Exposure
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

NCT06026514
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
B/HPIV3/S-6P
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 26, 2026, 5:19 AM EDT
Withdrawn Phase 2 Interventional

RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

NCT04433078
View directory record Official record
Conditions
Cytokine Storm, SARS-CoV-2
Interventions
Doxycycline, Placebo
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 2 Interventional Results available

Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

NCT04463004
View directory record Official record
Conditions
COVID-19, Sars-CoV2, Pneumonia
Interventions
Mavrilimumab, Placebos
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

NCT05263921
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

NCT05472038
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1), BNT162b2 Bivalent (WT/OMI BA.4/BA.5), BNT162b5 Bivalent (Original/OMI BA.4/BA.5), BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Monovalent (OMI BA.4/BA.5)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
12 Years and older
Enrollment
1,453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
31
States / cities
Anaheim, California • San Diego, California • Valley Village, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC

NCT05514691
View directory record Official record
Conditions
COVID-19 Virus Infection, COVID-19, Coronavirus Disease-19, COVID-19 Pandemic, SARS-CoV-2 Infection
Interventions
iStatis COVID-19 Ag Rapid Test, "COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America ("Labcorp")
Diagnostic Test
Lead sponsor
bioLytical Laboratories
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Elkridge, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 26, 2026, 5:19 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Asymptomatic and Pre-symptomatic Transmission of SARS-CoV-2 in a Community Congregant Setting

NCT05145803
View directory record Official record
Conditions
COVID-19, SARS-CoV2 Infection
Interventions
Polyvinylalcohol strip [diagnostic]
Device
Lead sponsor
Colorado School of Public Health
Other
Eligibility
18 Years and older
Enrollment
3,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for Mechanically Ventilated Population

NCT04388527
View directory record Official record
Conditions
Covid-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 26, 2026, 5:19 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19

NCT06923137
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), COVID-19 Vaccination, COVID-19 Vaccines, SARS-CoV-2 Infection, COVID19, SARS-CoV-2 Infection, COVID-19
Interventions
BNT162b2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

NCT05972993
View directory record Official record
Conditions
COVID-19
Interventions
mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg, Placebo, mRNA-CR-04 vaccine 3μg
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 26, 2026, 5:19 AM EDT
Recruiting Phase 1 Interventional

T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients

NCT05141058
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Coronavirus-specific T cell (CST)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 26, 2026, 5:19 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

NCT05475821
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-990, Placebo for ABBV-990
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 26, 2026, 5:19 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2

NCT04887948
View directory record Official record
Conditions
Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
Interventions
20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
27
States / cities
Anaheim, California • Walnut Creek, California • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 26, 2026, 5:19 AM EDT
Completed No phase listed Observational

eVusheld Assessment reaL wORld Effectiveness at UPMC

NCT05667116
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
EVUSHELD
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
4,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 26, 2026, 5:19 AM EDT